Jonathan Smith
Direktor/Vorstandsmitglied bei Wound Ostomy Continence Nursing Certification Board
Profil
Jonathan F.
Smith is the founder of AlphaVax, Inc. He is currently the Director at Wound, Ostomy, & Continence Nursing Certification Board.
Previously, he served as the Chief Scientific Officer at Liquidia Technologies, Inc. and Emergent Travel Health, Inc. from 2012 to 2018.
He also worked as a Faculty Member at the University of Maryland and as the Chief-Viral Biology at the U.S.
Army Medical Research Institute for Infectious Diseases.
Smith received his undergraduate degree from Colby College and his doctorate from The University of Texas at Austin.
Aktive Positionen von Jonathan Smith
| Unternehmen | Position | Beginn |
|---|---|---|
| Wound Ostomy Continence Nursing Certification Board | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jonathan Smith
| Unternehmen | Position | Ende |
|---|---|---|
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2018 |
| U.S. Army Medical Research Institute for Infectious Diseases | Corporate Officer/Principal | - |
| University of Maryland | Corporate Officer/Principal | - |
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Gründer | - |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jonathan Smith
| Colby College | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
| Wound Ostomy Continence Nursing Certification Board |
